The effects of thoracic epidural analgesia on oxygenation and pulmonary shunt fraction during one-lung ventilation: an meta-analysis

Xiao-Qian Li, Wen-Fei Tan, Jun Wang, Bo Fang and Hong Ma*

Abstract

Background: The aim of our study is to compare the effects of thoracic epidural analgesia combined with general anesthesia (GA) vs. general anesthesia on oxygenation and pulmonary shunt fraction during one-lung ventilation (OLV).

Methods: Literature research was firstly conducted for studies related to comparison of epidural anesthesia combined with GA vs. GA with reporting of hemodynamic and oxygenation variables and published from Jan 1990 to Jan 2014 in EMBAS, MEDLINE and Cochrane Central Register of Controlled Trials databases. The studies were reviewed and data were extracted and analyzed using fixed-effect and random-effect models.

Results: There are 14 trials with 60 separate comparisons enrolling 653 patients for analysis. Regarding systemic hemodynamics, thoracic epidural analgesia decreased the mean arterial pressure and mean pulmonary arterial pressure with weighted mean difference 95 % confidence interval (−6.64 [−9.57 to −3.71] vs. −6.33 [−9.25 to −3.41] and −3.18 [−5.07 to −1.28] vs. −2.05 [−3.35 to −0.75]) respectively at the two measurements time, however, only decreasing heart rate and systemic vascular resistance (−3.28 [−5.98 to −0.67] and −319.99 [−447.05 to −192.94]) over the first 30 min after OLV. For oxygenation variables, thoracic epidural analgesia is associated with significant reduction in partial arterial oxygen pressure, mixed arterial saturation of oxygenation and increased pulmonary venous admixture fraction compared to general anesthesia with weighted mean difference 95 % confidence interval (−104 [−136 to −71.05] vs. −14.23 [−20.81 to −7.65]), (0.74 [0.33 to 1.15] vs. −0.63 [−1.23 to −0.04]) and (2.53 [1.35 to 3.72] vs. 2.77 [1.81 to 3.74]) respectively before and after 30 min of one-lung ventilation. A decrease in mixed venous saturation of oxygenation occurred after 30 min of OLV (−2.39 [−3.73 to −0.99]). Besides, a higher mean value of airway pressure was found in the thoracic epidural analgesia with weighted mean difference 95 % confidence interval (1.95 [1.61 to 2.28] vs. 0.87 [0.54 to 1.20]) at the measurements.

Conclusion: Based on the existing limited data puts forward recommendations for cautious usage of thoracic epidural analgesia in case of underlying risks in lower systemic hemodynamics, decreased partial arterial oxygen pressure but increases pulmonary shunt during one-lung ventilation.

Keywords: One-lung ventilation, Oxygenation, Pulmonary shunt fraction, Thoracic epidural analgesia
Background

One-lung ventilation (OLV) in the lateral position is the unique character of the thoracic surgery. During the procedure, with a potential risk of increased pulmonary shunt and occurrence of hypoxemia, the physiologic defense mechanism, termed hypoxic pulmonary vasoconstriction (HPV), starts with a rapid onset [1]. HPV is generally considered to be a factor of governing the redistribution of blood flow to prevent partial arterial oxygen pressure (PaO2) from excessively decreasing and to optimize pulmonary gas exchange during OLV. This physiologic response may be altered by many factors and the effects on oxygenation or HPV should be taken into consideration when choosing the anesthetic regimen. It was suggested that the usage of thoracic epidural anesthesia (TEA) may provide adequate analgesia, reduce postoperative morbidity, improve pulmonary outcomes and facilitate fast-track approach for patients undergoing thoracic surgery [2–4]. Currently, continuous TEA combined with general anesthesia has been recommended widely in patients undergoing thoracic surgery. Due to the fact that pulmonary vasculature is dominant in sympathetic tone, it may be influenced by segmental blocking the activity of the sympathetic system over the vascular pulmonary responses. However, experimental and clinical studies on controversial effects of TEA with local anesthetics or opioids on HPV response during OLV are rare [5–7]. The optimal anesthetic management during OLV has not been yet clearly determined. Therefore, our meta-analysis is aiming to address this issue based on studies published over 15 years.

Methods

All experimental procedures listed below were approved by the Ethics Committee of China Medical University and were performed in accordance with the Helsinki Declaration for Medical Research Involving Human Subjects (the World Medical Association, Finland, created in 1964 and revised 2013).

Literature review

This meta-analysis was performed with a prospective protocol (outline below) using recommended literature search strategies incorporating multiple search terms. The literature search was performed in EMBAS, MEDLINE and the Cochrane central register of Controlled Trials databases published from Jan 1990 to Jan 2014 for the trials related to thoracic epidural anesthesia. Thoracic epidural analgesia, thoracic epidural block or ‘epidural-general’ were combined with procedure specific search terms (one-lung ventilation, intrapulmonary shunt) and limited by Human and Clinical trials. For the TEA portion, MESH term thorax, epidural, anesthesia AND text word thoracic epidural anesthesia were used and combined with OR (n = 1603). MESH term thorax, analgesia, epidural and the word thoracic epidural analgesia were used and combined with OR (n = 1292). MESH term lung, ventilation, respiration and text word one lung ventilation were used to search the database and combined with the term OR (7902). The primary investigations of 14 trials were acquired when all search terms were combined with the term AND. Each was then further checked by another two authors for any additional studies, as were the author’s personal files for additional references that met all inclusion criteria.

Study inclusion criteria

Thoracic epidural anesthesia (TEA) is defined as medicine delivered into the thoracic epidural space by injection or repeated bolus dosing local anesthetics (LA) or opioids. Studies given only a single epidural dose at the beginning or end of surgery (single shot) were not included.

Among all trials included in our meta-analysis, adult patients (aged ≥18 years) were randomly assigned to one of the two groups: general intravenous or inhalation anesthesia (GA group); general anesthesia combined with TEA (TEA group). The observed variables are the hemodynamic changes, arterial and mixed venous blood gas analysis and the effects of on intrapulmonary shunt fraction during OLV. Non-English language reports were excluded.

Methodological qualities of included studies are graded using Cochrane scoring systems with a 5-point scale, in which a score of 1 is given for each of the following: 1) the description of the study as randomized, 2) the description of an appropriate method of randomization, 3) the description of the study as double-blinded, 4) the description of an appropriate method of double-blinding and 5) a statement of withdrawals. Since nonrandomized studies are excluded, the minimum score is one and the maximum is five.

However, there are very few studies completely satisfied with all the criteria above. Hence, good-quality studies (prospective, randomized, and controlled) are included without weight by sample size. Any disputes were resolved by agreement of at least two reviewers.

Data extraction and statistical analysis

Study information was summarized and listed in Table 1. The comparisons of intraoperatively hemodynamic parameters, blood gas analysis and secondary outcomes calculated by the standard formulas, such as mixed venous blood gas analysis and pulmonary shunt fraction during OLV are included. The comparisons in trials were then analyzed independently. Patients were subgrouped...
Table 1: Included randomized controlled trials for effects of thoracic epidural analgesia on oxygenation and pulmonary shunt fraction during one-lung ventilation

| Study       | Participants | Interventions                                                                 | Abstracted outcomes                                      |
|-------------|--------------|--------------------------------------------------------------------------------|-----------------------------------------------------------|
| Ozcan et al. [5] | 25 G-TIVA    | G-TIVA/ISO induced: fentanyl (3 μg·kg⁻¹), propofol (BIS < 45), vecuronium (0.1 mg·kg⁻¹) | hemodynamic variables: HR, MAP; Intrapulmonary shunt: PvO₂, PaO₂, Qs/Qt |
|             | 25G-TIVA-TEA | Maintained: propofol or isoflurane respectively (according to BIS value)       |                                                           |
|             | 25 G-ISO     | G-TIVA/ISO-TEA: T7-T8 epidural with initial 2 % lidocaine 2 mL, 0.1 % bupivacaine +0.1 mg·kg⁻¹ morphine 10 mL, then induced the same as G-TIVA/ISO group |                                                           |
| Garutti et al. [6] | 30 G-TIVA    | G-TIVA: induced: fentanyl (3 μg·kg⁻¹), midazolam (2-3 mg), propofol (2 mg/kg), rocuronium (0.6 mg/kg) | hemodynamic variables: HR, MAP; Intrapulmonary shunt: PvO₂, PaO₂, Qs/Qt, PaCO₂, PH, SvO₂, SaO₂, CaO₂, CvO₂, Other: Hb, Paw |
|             | 30 G-TIVA-TEA | Maintained: fentanyl (3 μg·kg⁻¹), propofol (6–7 mg·kg⁻¹·h⁻¹); rocuronium (0.5 mg·kg⁻¹·h⁻¹) |                                                           |
|             | 13G-TIVA     | G-TIVA-TEA: T6-T7 or T7-T8 epidural with initial 6–8 mL bupivacaine, then induced: same as G-TIVA group |                                                           |
|             | 13G-TIVA-TEA-B | Maintained: 0.375 % bupivacaine (6–7 mL·h⁻¹), propofol (6–7 mg·kg⁻¹·h⁻¹), rocuronium (0.6 mg/kg) |                                                           |
|             | 13G-TIVA-TEA-S | Maintained: fentanyl (50–100 μg), propofol (4–5 μg/ml), vecuronium (0.1 mg·kg⁻¹) |                                                          |
|             |              | Maintained: 20 μg/ml remifentanil, 0.2 ml·kg⁻¹·h⁻¹; vecuronium (2–2.5 mg·h⁻¹), propofol (according to BIS) |                                                          |
|             | 35 G-TIVA-TEA | G-TIVA-TEA: T6-T7 or T7-T8 epidural with initial meperidine 2 mg·kg⁻¹ diluted in a volume of 10–12 mL, then induced: same as G-TIVA group |                                                          |
|             |              | Maintained: fentanyl (2–3 μg·kg⁻¹), propofol (6–7 mg·kg⁻¹·h⁻¹); rocuronium (0.5 mg·kg⁻¹·h⁻¹) |                                                          |
| Jung et al. [8]      | 13G-TIVA     | G-TIVA-TEA-B: T5-T6 or T6-T7 epidural with initial 10 mL 5 % bupivacaine, then induced: same as G-TIVA group |                                                          |
|             | 13G-TIVA-TEA-S | Maintained: 0.25 % bupivacaine 0.1 ml·kg⁻¹·h⁻¹, propofol (6–7 mg·kg⁻¹·h⁻¹), vecuronium (2–2.5 mg·h⁻¹), propofol (according to BIS) |                                                          |
| Garutti et al. [9]   | 37 G-TIVA    | G-TIVA-TEA-S: T5-T6 or T6-T7 epidural with initial 10 mL 5 % bupivacaine, then induced: same as G-TIVA group |                                                          |
|             |              | Maintained: 1 μg/ml sufentanil 0.1 ml·kg⁻¹·h⁻¹, propofol (6–7 mg·kg⁻¹·h⁻¹), vecuronium (2–2.5 mg·h⁻¹), propofol (according to BIS) |                                                          |
| Dosso et al. [10]    | 35 G-TIVA-TEA | G-TIVA-TEA: T6-T7 or T7-T8 epidural with initial meperidine 2 mg·kg⁻¹ diluted in a volume of 10–12 mL, then induced: same as G-TIVA group |                                                          |
|             |              | Maintained: propofol (6–7 mg·kg⁻¹·h⁻¹), vecuronium (0.5 mg·kg⁻¹·h⁻¹) |                                                          |
| Feng Y et al. [11]   | 12G-TIVA     | G-TIVA-TEA-B: T5-T6 or T6-T7 epidural with initial 1 % lidocaine 5 mL, then induced: same as G-TIVA group |                                                          |
|             |              | Maintained: propofol (9–12 mg·kg⁻¹·h⁻¹), vecuronium (0.1 mg·kg⁻¹), T₇₋₈ or T₈₋₉ epidural with initial 1 % lidocaine 5 mL, then induced: same as G-TIVA group |                                                          |

Intrapulmonary shunt: PaO₂/PaCO₂, Hb, Paw, Other: Hb, Paw, CO, SvO₂, SaO₂, CaO₂, CvO₂.
| Study | Protocol | Epidual Anesthesia | Hemodynamic Variables | Intrapulmonary Shunt |
|-------|----------|--------------------|-----------------------|---------------------|
| Li et al. [12] | 10 G-SEV-TEA | G-SEV: induced: fentanyl (100 μg), propofol (2 mg.kg⁻¹), vecuronium (0.1 mg.kg⁻¹) | PaO₂, PaCO₂, P₇₅CO₂ | Other: Hb, Paw |
| Wang et al. [13] | 30 G-TIVA-TEA | G-TIVA: induced: fentanyl (2 μg.kg⁻¹), midazolam (0.1 mg.kg⁻¹), propofol (1.2–2.0 mg.kg⁻¹), vecuronium (0.1 mg.kg⁻¹) | Intrapulmonary shunt: PaO₂, PaCO₂, Qs/Qt |
| Wang et al. [14] | 16 G-ISO-TEA | G-ISO: induced: fentanyl (2 μg.kg⁻¹), midazolam (0.1 mg.kg⁻¹), propofol (1.0–2.0 mg.kg⁻¹), vecuronium (0.16 mg.kg⁻¹) | Hemodynamic variables: HR, MAP; Intrapulmonary shunt: PaO₂, PaCO₂, PVg/Qs |
| Wang et al. [15] | 15 G-ISO-TEA | G-ISO: induced: fentanyl (2 μg.kg⁻¹), midazolam (0.05 mg.kg⁻¹), propofol (1.5–2.0 mg.kg⁻¹), vecuronium (0.1 mg.kg⁻¹) | Hemodynamic variables: HR, MAP; Intrapulmonary shunt: PaO₂/FiO₂, Qs/Qt Other: Paw |
| Chen et al. [16] | 13 G-TIVA-TEA | G-TIVA: induced: fentanyl (3 μg.kg⁻¹), midazolam (0.1 mg.kg⁻¹), propofol (1.0–2.0 mg.kg⁻¹), vecuronium (0.1 mg.kg⁻¹) | Hemodynamic variables: HR, MAP; Intrapulmonary shunt: PaO₂/PaCO₂/PvO₂/Qs/Qt, SVO₂, SaO₂, CaO₂, CvO₂, P₇₅CO₂, pH; Other: Paw |
| Wu et al. [17] | 41G-TIVA-TEA | G-TIVA: induced: midazolam (0.05 mg.kg⁻¹), fentanyl, propofol and vecuronium (no details) | Hemodynamic variables: HR, MAP; Intrapulmonary shunt: PaO₂/PaCO₂/PvO₂/Qs/Qt, pH |
by different medications in epidural catheter of TEA group or different anesthetic regimens in GA group.

Quantitative analyses were performed using Review Manager Software (version 5.0; Cochrane Collaboration, Oxford shire, England). The level of significance for all tests is set at a $\alpha$ level of 0.05. For dichotomous data, Petro odds ratios (ORs) with 95 % confidence intervals (CIs) were computed. When possible, data were converted to means and standard deviations (SD) for continuous outcomes and calculated as weighted mean differences with 95 % CIs between active and control groups for each study. For heterogeneity analyses: data that were not significantly homogeneous ($P > 0.1$) were analyzed with a fixed-effect model, whereas heterogeneous data ($P \leq 0.1$) were analyzed with a random effect model. Sensitivity analyses were performed to identify sources of heterogeneity. Studies which do not report mean and SD or standard error of the mean (SEM) are not included in the meta-analysis.

**Results**

**Retrieved and included studies**

Fourteen reports were retrieved while one trial with self-comparison was rejected (Fig. 1). A total of 653 patients with 60 separate comparisons met all inclusion criteria [5, 6, 8–19] (Table 1). These reports were published between

---

**Table 1** Included randomized controlled trials for effects of thoracic epidural analgesia on oxygenation and pulmonary shunt fraction during One-lung ventilation (Continued)

| Study            | TEA therapy | GA therapy | Hemodynamic variables | Pulmonary shunt | Notes |
|------------------|-------------|------------|-----------------------|-----------------|-------|
| Zhang et al. [18]| G-TIVA: induced: midazolam (0.05 mg.kg⁻¹), fentanyl, propofol and vecuronium (no details) | 43G-TIVA: induced: fentanyl, propofol and vecuronium (no details, according to BIS). | PaO₂, PaCO₂, Qs/Qt |  |  |
| Sun et al. [19]  | G-ISOL-TEA and G-TIVA-TEA: induced: T₇₋₈ or T₈₋₉ epidural with initial 0.5 % ropivacaine 7–9 ml then induced with fentanyl (3 μg.kg⁻¹), midazolam (2-3 mg), propofol (1.5 mg.kg⁻¹), vecuronim (0.1 mg.kg⁻¹) | G-TIVA-TEA: T₅₋₆ or T₆₋₇ epidural with initial 0.5 % ropivacaine 7–12 ml then induced as G-TIVA. Maintained: epidural with 0.5 % ropivacaine 4–6 ml.h⁻¹, combined with propofol and vecuronium (no details). | PaO₂, PaCO₂, Qs/Qt, pH |  |  |

TEA thoracic epidural anesthesia with local anesthetic, opioids or both, TIVA total-intravenous anesthesia, ISO isoflurane inhalation anesthesia

---

**Fig. 1** The flow diagram of retrieved, excluded, and analyzed trials. * Cochrane Central Register of Controlled Trials. † Continuous data presented as means but without standard deviation, no dichotomous data. RCT indicates randomized controlled trials.
1999 and 2010 and reported data were from 653 patients. Forty one studies were excluded: 1) not thoracic surgery; 2) no available data on observed indexes; 3) the intervention used in studies not consistent with the criteria.

Among included trials, the epidural catheter was all placed at T₆₋₇, T₇₋₈ or T₈₋₉ interspace in the TEA group and continuously injected with local anesthetics, opioids or both via the catheter during the whole OLV procedure more than 30 min. Controls received intravenous opioids with or without nonopioid analgesics (Table 1).

Risk of bias in included studies
Overall study quality was moderate. There was adequate randomization in 10/14 (71.4 %) of studies, double-blinding in 12/14 (85.7 %) of studies and statement of withdraw in 3/14 (21.4 %) of studies. Three studies were assessed all in three domains and five studies were assessed in two domains.

Thoracic Epidural analgesia on systemic hemodynamics variables
Overall, it was shown that TEA did not significantly affect the changes of hemodynamic variables during two lung ventilation, and it is associated with significantly reduction in heart rate (HR) and systemic vascular resistance (SVR) only during OLV within 30 min. However, there was a continuously significant decrease in mean arterial pressure (MAP) and mean pulmonary arterial pressure (MPAP) during the whole OLV period until re-two lung ventilation (re-TLV) (Table 2).

Thoracic Epidural analgesia on oxygenation and pulmonary shunt fraction variables
It was shown that TEA did not significantly affect the pulmonary shunt fraction during TLV. From TLV to OLV, TEA modestly reduced arterial oxygen pressure (PaO₂), mixed arterial saturation of oxygenation (SaO₂) and increased the pulmonary venous admixture fraction (Qs/Qt%) and mean airway pressure (Paw) occurred during OLV. A decrease in mixed venous saturation of oxygenation (SvO₂) occurred after 30 min of OLV (Fig. 2, Table 3).

To overcome clinical heterogeneity, data were pooled for sensitivity analysis between different techniques of general anesthesia (e.g. total intravenous anesthesia vs. balanced anesthesia) and types of medications in epidural catheter of TEA group. There were no obviously differences in all observed variables. However, no pooling of data from epidural anesthesia with different local anesthetics was possible for small number of studies.

Discussion and conclusions
The anesthetic technique is one of several factors that can affect oxygenation and hemodynamics during one-lung ventilation (OLV), among which thoracic epidural analgesia (TEA) has demonstrated to provide statistically better acute pain relief after thoracotomy and now widely used in clinic [2, 3]. However, there were few and contradictory studies considering the effects of TEA on hemodynamics and oxygenation changes during the procedure of OLV [5, 6, 9]. This is the first meta-analysis comparing the effects of TEA on oxygenation and pulmonary shunt fraction during OLV. The most significant finding of our meta-analysis is an equivalent effect of combining TEA with any technique of general anesthesia (GA) on hemodynamic and oxygenation variables in patients undergoing OLV after re-conversion to TLV in supine position, having positive effects on patient safety during surgery. However, the current study demonstrates that TEA inhibited hypoxic pulmonary vasoconstriction (HPV) as producing larger shunt fractions and lower PaO₂, accompanied with decreased systemic hemodynamics compared with GA after undergoing OLV for more than 30 min. It is consistent with recent studies, in which the authors showed that, an increase in Qs/Qt was accompanied with a decrease in PaO₂, but cardiac output (CO) and pulmonary artery pressure (PAP) were preserved between the groups [7, 20, 21]. At the same time, TEA was found to be associated with lower MPAP in line with decreased MAP and SVR, whereas CO was comparable. Ephedrine is a partial α- and β-agonist. All trials included in our meta-analysis showed a tendency towards lower mean arterial blood pressure in the TEA group, which was treated by administering a dose of 5 or 10 mg ephedrine intravenously. Mechanism leading to less marked effects on CO was attributed to the higher incidence of ephedrine use in TEA groups. It had significant vasopressor activity in the pulmonary vascular bed that predominantly mediated by α-adrenergic receptor activation, although ephedrine dose less than 0.15 mg/kg did not increase the intrapulmonary shunt during OLV [8, 10]. Additionally, increasing in HR and ventricular contractility strength by β-adrenergic subtype activation in left ventricular tissue could also explain the similarity of the compared values of CO [10]. Hence, the decrease in oxygenation was secondary to the effect of TEA on HPV and probably not on the changes of CO.

The pulmonary vasculature is dominant in sympathetic activity by the norepinephrine released from sympathetic nerve endings [6, 9, 22]. Potential mechanism of the influence of pulmonary shunt fraction during OLV was prone to cardiovascular and hemodynamic effects of TEA. Decrease in HR, MAP, stoke volume due to blockade of sympathetic activity over the vascular pulmonary responses was shown closely associated with decreased PaO₂ [6, 9]. The decreased PaO₂ may further have an opposite effects on HPV [5, 6, 23]. It may produce
vasodilatation of the pulmonary vessels by blocking the activity of the thoracic sympathetic response [24] or stimulate precapillary vasoconstriction via a pathway involving NO and/or cyclooxygenase synthesis inhibition [17]. In an animal study by Ishibe, TEA was demonstrated to affect the ventilation/reperfusion relationship by stimulating precapillary vasoconstriction to redistribute pulmonary blood flow away from hypoxic lung regions to the other well oxygenated areas of the lung [7], which was consistent with the study of Garutti I [6].

However, similar but significant differences in magnitude of changes in pulmonary hemodynamic circulation accorded with systemic in both groups may contribute to the analgesic effect of TEA or the systemic effects of the absorption of the local anesthetics for overall reduced sympathetic tone, and blockade of cardiac accelerator fibers [6]. The principal weakness of our meta-analysis is that we combined data for comparison even with some studies which were heterogeneous such as epidural treatments with different drugs (e.g. local

Table 2 Effects of thoracic epidural analgesia on hemodynamics variables during OLV

| Effect of OLV | All available data | No. of comparisons | TEA group | GA group | WMD (95 % CI) | P value |
|---------------|-------------------|--------------------|-----------|----------|---------------|---------|
| During two-lung ventilation | | | | | | |
| HR (beat/min) | 7 | 72.98 (68.80 to 83.00) | 73.71 (69.00 to 78.00) | −1.33 [−5.16 to 2.50] | 0.50 |
| MAP (mmHg) | 5 | 83.62 (76.00 to 87.00) | 86.26 (75.00 to 93.00) | −2.28 [−5.51 to 0.95] | 0.17 |
| CO (L/min) | 2 | 5.50 (5.20 to 5.80) | 4.90 (4.90 to 4.90) | 0.55 [−0.21 to 1.30] | 0.16 |
| CVP (cmH2O) | 3 | 7.00 (6.00 to 8.00) | 8.00 (6.00 to 9.00) | −1.00 [−3.94 to 1.95] | 0.51 |
| SVR (dynes·sec·cm⁻⁵) | 3 | 1180.70 (1022.00 to 1308.00) | 1401.67 (1395.00 to 1405.00) | −246.16 [−408.55 to −83.77] | 0.29 |
| MAP (mmHg) | 3 | 20.67 (18.00 to 22.00) | 18.67 (18.00 to 19.00) | 2.09 [−0.94 to 5.13] | 0.18 |
| PAOP (mmHg) | 2 | 12.50 (12.00 to 13.00) | 13.00 (13.00 to 13.00) | −0.59 [−2.48 to 1.31] | 0.55 |
| During one-lung ventilation within 30 min | | | | | | |
| HR (beat/min) | 7 | 74.14 (66.00 to 85.00) | 75.48 (73.20 to 80.00) | −3.32 [−5.89 to −0.67] | 0.01 |
| MAP (mmHg) | 7 | 85.11 (81.00 to 89.00) | 93.29 (87.60 to 100.00) | −6.64 [−9.57 to −3.71] | <0.01 |
| CO (L/min) | 2 | 5.40 (5.40 to 5.40) | 5.70 (5.70 to 5.70) | 0.30 [−1.15 to 0.55] | 0.49 |
| CVP (cmH2O) | 3 | 8.30 (7.00 to 10.00) | 9.00 (8.00 to 11.00) | −0.61 [−1.72, 0.49] | 0.28 |
| SVR (dynes·sec·cm⁻⁵) | 3 | 1003.33 (890.00 to 1124.00) | 1349.67 (1141.00 to 1454.00) | −319.99 [−447.05 to −192.94] | <0.01 |
| MAP (mmHg) | 3 | 20.00 (19.00 to 22.00) | 23.00 (23.00 to 23.00) | −3.18 [−5.07 to −1.28] | <0.01 |
| PAOP (mmHg) | 2 | 12.00 (12.00 to 12.00) | 13.00 (13.00 to 13.00) | −1.00 [−2.87 to 0.87] | 0.30 |
| One-lung ventilation more than 30 min | | | | | | |
| HR (beat/min) | 6 | 76.00 (75.00 to 87.00) | 75.32 (71.50 to 80.00) | −0.94 [−3.81 to 1.92] | 0.52 |
| MAP (mmHg) | 6 | 84.12 (75.00 to 87.00) | 91.85 (85.80 to 98.00) | −6.33 [−9.25 to −3.41] | <0.01 |
| CO (L/min) | 4 | 5.55 (4.70 to 6.10) | 5.55 (5.50 to 5.60) | −0.07 [−0.64 to 0.51] | 0.82 |
| CVP (cmH2O) | 4 | 7.75 (7.00 to 9.00) | 8.00 (7.00 to 9.00) | −0.37 [−1.24 to 0.51] | 0.41 |
| SVR (dynes·sec·cm⁻⁵) | 4 | 1168.50 (981.00 to 1356.00) | 1209.00 (1209.00 to 1209.00) | −38.17 [−201.75 to 125.42] | 0.07 |
| MAP (mmHg) | 4 | 20.00 (19.00 to 21.00) | 22.50 (22.00 to 23.00) | −2.05 [−3.35 to −0.75] | <0.01 |
| PAOP (mmHg) | 4 | 12.50 (12.00 to 13.00) | 13.50 (13.00 to 14.00) | −1.11 [−2.40 to 0.18] | 0.09 |
| Re-two ventilation | | | | | | |
| HR (beat/min) | 5 | 74.40 (65.00 to 87.00) | 71.60 (67.00 to 78.00) | −0.41 [−4.08 to 3.25] | 0.82 |
| MAP (mmHg) | 5 | 84.40 (81.00 to 87.00) | 95.80 (92.00 to 95.00) | −11.83 [−15.87 to −7.79] | <0.01 |
| CO (L/min) | 2 | 5.55 (5.50 to 5.60) | 5.20 (5.20 to 5.20) | 0.35 [−0.58 to 1.29] | 0.46 |
| CVP (cmH2O) | 3 | 7.67 (7.00 to 9.00) | 6.33 (6.00 to 7.00) | 1.20 [−0.15 to 2.55] | 0.08 |
| SVR (dynes·sec·cm⁻⁵) | 3 | 1157.00 (1052.00 to 1316.00) | 1358.67 (1226.00 to 1425.00) | −186.69 [−312.37 to −61.01] | <0.01 |
| MAP (mmHg) | 3 | 19.67 (18.00 to 21.00) | 21.33 (21.00 to 22.00) | −1.77 [−3.61 to 0.07] | 0.06 |
| PAOP (mmHg) | 2 | 11.00 (10.00 to 12.00) | 12.00 (12.00 to 12.00) | −1.03 [−2.75 to 0.68] | 0.24 |

Data were presented as Mean and range in bracket
anesthetics, opioids etc.) or different patient population. On the other hand, more significant differences might attain when better designed published trails with large sample size become available.

Another main reason for failing to show the beneficial effect of TEA during OLV was that in clinical circumstances, there were several other factors affecting HPV in different direction, finally resulting in clinically significant net effects. In our study, TEA was associated with higher mean airway pressure in the dependent lung compared with GA, which may counteract HPV in the non-dependent lung by diverting blood flow away from the ventilated lung, thereby increasing the pulmonary shunt. Besides, the decreased SvO₂ in the TEA after 30 mins of OLV in addition to changes in shunt fraction may better explain the mechanism of our obverted oxygenation changes. Furthermore, there is essentially uncharged PaCO₂ in both groups. Though, the efficacy of HPV in hypoxic lung regions is increased in the presence of respiratory acidosis and inhibited by respiratory

---

### Fig. 2

Effect of thoracic epidural analgesia (TEA) on pulmonary venous admixture fraction (Qs/Qt) in general anesthesia (GA) combined with TEA group and GA group during mechanical ventilation: Forest plot showing pooled analysis of the WMD of Qs/Qt in two groups during two-lung ventilation (01), one-lung ventilation within 30 min (02), one-lung ventilation more than 30 min (03) and re-two-lung ventilation (04) based on the fixed effects model. CI = confidence interval.
Table 3 Effects of thoracic epidural analgesia on oxygenation and pulmonary shunt fraction variables during OLV

| All available data | No. of comparisons | TEA group | GA group | WMD (95 % CI) | P value |
|--------------------|--------------------|-----------|----------|---------------|---------|
| During two-lung ventilation | PaO2 (mmHg) 13 | 382.42(205.00 to 85.00) | 377.92(191.0 to 453.00) | 6.29 [0.04 to 12.17] | 0.35 |
| PaCO2 (mmHg) 10 | 39.67 (32.50 to 37.6) | 40.23 (35.60 to 37.40) | -0.21 [-1.11 to 0.68] | 0.64 |
| PV (mmHg) 7 | 51.50(48.00 to 55.00) | 51.62(48.0 to 53.30) | 0.27 [-1.51 to 2.06] | 0.76 |
| Qs/Qt (%) 13 | 14.80 (4.90 to 22.50) | 15.50 (3.95 to 21.60) | 0.02[0.47 to 0.50] | 0.95 |
| SvO2 (%) 4 | 85.37(83.30 to 87.10) | 86.68(84.90 to 88.20) | -1.22 [-2.36 to -0.07] | 0.58 |
| SaO2 (%) 4 | 99.70(99.00 to 99.90) | 99.45(99.00 to 99.90) | 0.24 [-0.08 to -0.04] | 0.32 |
| PH 4 | 7.43 (7.42 to 7.43) | 7.44 (7.43 to 7.44) | -0.01 [-0.02 to 0.00] | 0.21 |
| Paw (cmH2O) 4 | 19.83 (17.00 to 20.00) | 19.03 (17.00 to 21.40) | -0.24 [-1.14 to 0.66] | 0.60 |

During one-lung ventilation within 30 min

| PaO2 (mmHg) 10 | 166.90(118.00 to 211.00) | 171.2(122.00 to 201.00) | -16.52 [-21.98 to -11.05] | <0.01 |
| PaCO2 (mmHg) 10 | 37.12 (36.10 to 44.20) | 36.85(34.20 to 42.20) | 0.29 [-0.53 to 1.10] | 0.49 |
| PV (mmHg) 7 | 47.78(44.90 to 54.00) | 46.14(44.50 to 51.00) | 1.13 [-0.50 to 2.76] | 0.17 |
| Qs/Qt (%) 10 | 33.32 (27.30 to 39.50) | 32.77 (26.70 to 40.60) | 2.53 [1.35 to 3.72] | <0.01 |
| SvO2 (%) 4 | 80.53(78.80 to 82.60) | 81.58(78.40 to 84.20) | -1.13 [-2.74 to 0.48] | 0.27 |
| SaO2 (%) 4 | 97.98(96.80 to 99.30) | 97.65(97.30 to 98.00) | 0.74[0.33 to 1.15] | <0.01 |
| PH 4 | 7.43 (7.42 to 7.44) | 7.44 (7.42 to 7.46) | -0.01 [-0.02 to 0.001] | 0.41 |
| Paw (cmH2O) 4 | 28.00 (23.00 to 32.50) | 27.00 (24.00 to 30.90) | 1.95 [1.61 to 2.28] | <0.01 |

One-lung ventilation more than 30 min

| PaO2 (mmHg) 11 | 162.27(117.00 to 203.00) | 168.72(148.00 to 221.00) | -14.23 [-20.81 to -7.65] | <0.01 |
| PaCO2 (mmHg) 11 | 36.61 (33.90 to 44.60) | 36.78 (35.00 to 44.20) | -0.22 [-0.96 to 0.53] | 0.57 |
| PV (mmHg) 6 | 44.70(42.60 to 46.10) | 44.98(43.40 to 46.60) | -0.61 [-2.23 to 1.02] | 0.46 |
| Qs/Qt (%) 12 | 34.40 (33.60 to 42.70) | 32.67 (32.10 to 40.90) | 2.77 [1.81 to 3.74] | <0.01 |
| SvO2 (%) 6 | 79.33(77.40 to 81.10) | 81.97(78.50 to 83.90) | -2.39 [-3.73 to -0.99] | <0.01 |
| SaO2 (%) 6 | 97.68(96.60 to 98.10) | 98.20(97.20 to 99.00) | -0.63 [-1.23 to -0.04] | 0.04 |
| PH 6 | 7.43 (7.43 to 7.44) | 7.44 (7.41 to 7.46) | 0.00 [-0.01 to 0.01] | 0.50 |
| Paw (cmH2O) 6 | 26.80 (24.00 to 32.50) | 26.72 (24.00 to 31.40) | 0.87 [0.54 to 1.20] | <0.01 |

Re-two ventilation

| PaO2 (mmHg) 7 | 322.28(173.00 to 482.00) | 307.28(168.00 to 407.00) | 11.54 [-4.25 to 27.34] | 0.15 |
| PaCO2 (mmHg) 3 | 37.8 (34.00 to 46.10) | 35.6 (34.90 to 36.90) | -0.60 [-3.03 to 1.83] | 0.63 |
| PV (mmHg) 5 | 47.82(43.00 to 50.00) | 48.68(46.20 to 51.00) | 0.06 [-2.24 to 2.36] | 0.96 |
| Qs/Qt (%) 6 | 18.55(15.30 to 24.50) | 20.15(15.50 to 24.80) | -1.27 [-2.73 to 0.20] | 0.09 |
| SvO2 (%) 2 | 81.90(81.50 to 82.30) | 85.30(85.30 to 85.30) | -3.62 [-6.28 to -0.95] | 0.08 |
| SaO2 (%) 2 | 99.75(99.70 to 99.80) | 99.00(99.00 to 99.00) | 0.75[0.52 to 0.98] | 0.67 |
| PH 2 | 7.42 (7.41 to 7.42) | 7.42 (7.42 to 7.42) | 0.00 [-0.03 to 0.02] | 0.77 |
| Paw (cmH2O) 2 | 19.00 (18.00 to 20.00) | 18.00 (18.00 to 18.00) | 0.95 [-0.81 to 2.71] | 0.29 |

Data were presented as Mean and range in bracket.
Some limitations are inherent to our meta-analysis. Firstly, it is possible we have missed trial that satisfied the inclusion criteria, and some data have to be excluded as the reports are incomplete. Secondly, the quality of the randomized trials in the systemic review is varied. So few alternative protocols with small sample sizes have been studied in effects of TEA on oxygenation and pulmonary shunt fraction during OLV, and quantitative analyses were limited as a result of heterogeneity and outcomes measures. Epidural thoracic anesthesia can be performed with LA, opioids or both, which limits the studies with homogeneous design from which data can be pooled. The sensitivity analyses were only chosen according to the different anesthetic regimens of GA group, although it is unlikely that different subgroups would have changed our findings, such as re-subgrouped by the different medication of TEA group, use of right arterial blood samples instead of pulmonary arterial blood [5, 29] or different sympathetic block level.

Thirdly, the time intervals for outcome assessments were chosen with principle of the greatest degree of inclusion. Although the findings are reported as statistically significant, they are very discrete in clinical terms. It might be a possibility of different results because different measurements were evaluated after OLV, but it is still difficult to draw definite conclusions until further large, well conducted trials are performed. Nevertheless, the analyses performed with limited studies allowed us to put forward recommendations for cautious usage of TEA in counteracting HPV undergoing OLV by producing a larger shunt and a decrease in oxygenation during the OLV as the vasodilatation caused by sympathetic blockade.

Additional file

Additional file 1: PRISMA 2009 checklist. (DOC 68 kb)

Abbreviations
CIs: Confidence intervals; CO: Cardiac output; GA: General anesthesia; Hb: Hemoglobin; HR: Heart rate; HPV: Hypoxic pulmonary vasoconstriction; MAP: Mean arterial pressure; MPAP: Mean pulmonary arterial pressure; OLV: One-lung ventilation; ORs: Peto odds ratios; Paw: Mean airway pressure; PaO2: Partial arterial oxygen pressure; PAOP: Pulmonary artery occlusion pressure; Qs/Qt: Pulmonary venous admixture fraction; SD: Standard deviations; SEM: Standard error of the mean; SaO2: Mixed arterial saturation of oxygenation; SO2: Mixed venous saturation of oxygenation; TEA: Thoracic epidural anesthesia; TIVA: Total intravenous anesthesia; TLV: Two lung ventilation; WMD: Weighted mean difference.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XQL, WFT, JW and BF participated in the literature research and review. XQL, HM and WFT participated in data extraction, and performed most statistical analysis; BF, HM and W-FT performed in making inclusion criteria and statistical analysis; JW and HM participated involved in the guide of model design and study design; JW gave important directions to data analysis and manuscript writing. All authors read and approved the final manuscript.

Acknowledgments
Funding for this project was provided by Doctoral Fund of Ministry of Education of China, No. 20092104110009 and Natural Science Foundation of China, No. 81271370.

Received: 23 September 2014 Accepted: 10 November 2015
Published online: 19 November 2015

References
1. Karzai W, Schwarzkopf K. Hypoxemia during one-lung ventilation. Curr Opin Anesthesiol. 2009;22:1–3.
2. Guay J. The benefits of adding epidural analgesia to general anesthesia: a meta analysis. J. Anesth. 2006;20(4):335–40.
3. Popping DM, Elia N, Marret E, Remy C, Tramer MR. Protective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery. Arch Surg. 2008;143(10):990–9.
4. Lawrence VA, Cornell JE, Smetana GW. Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: systematic review of the American College of Physicians. Ann Intern Med. 2006;146(8):596–608.
5. Ozcan PE, Senturk M, Sungur Ulke Z, Toker A, Odzen E, Camci E. Effects of thoracic epidural anaesthesia on pulmonary venous admittance and oxygenation during one-lung ventilation. Acta Anesthesiol Scand. 2007;51:1117–22.
6. Garutti I, Quintana B, Olmedilla L, Cruz A, Baranco M, Garcia E. Arterial oxygenation during one-lung ventilation: Combined versus general anaesthesia. Anesth Analg. 1999;88:494–9.
7. Ishibe Y, Shikokawa Y, Umeda T, Uno H, Nakamura M, Iizumi T. The effect of thoracic epidural anaesthesia on hypoxic pulmonary vasoconstriction in dog: Analysis of the pressure-flow curve. Anesth Analg. 1996;82:1049–55.
8. Jung SM, Cho CK, Kim YJ, Cho HM, Kim CW, Kwon HU, et al. The effect of thoracic epidural anesthesia on pulmonary shunt fraction and arterial oxygenation during one-lung ventilation. J Cardiothorac Vasc Anesth. 2010;24(3):456–62.
9. Garutti I, Cruz P, Olmedilla L, Barino JM, Cruz A, Fernandez C, et al. Effects of thoracic epidural meperidine on arterial oxygenation during one-lung ventilation in thoracic surgery. J Cardiothorac Vasc Anesth. 2003;17(3):302–5.
10. Von Dossow V, Welte M, Zaune U, Martin E, Walter M, Rücker J, et al. Thoracic epidural anesthesia combined with general anesthesia: the preferred anesthetic technique for thoracic surgery. Anesth Analg. 2001; 92(4):848–54.
11. Feng Y, Sun Y, Yang BX. The effect of epidural ropivacaine on arterial oxygenation and intrapulmonary shunt during one-lung ventilation. Chin J Anesthesiol. 2003;22:143–7.
12. Lu JH, Chang YL, Niu L. The effect of epidural anesthesia combined with inhaled anesthesia on oxygenation during one-lung ventilation. Chin J Anesthesiol. 2003;22:171–2.
13. Wang ZY, Luo X, Wang DJ, Ma ZJ. Influence of general-thoracic epidural anesthesia on intrapulmonary shunt and blood oxygenation during one-lung ventilation. Modern Medical Journal. 2007;55:390–2.
14. Wang GM, Xu H, Zeng YM. The effect of epidural anesthesia combined with propofol intravenous anesthesia on intrapulmonary shunt during one-lung ventilation. Jovial Practice Medicine. 2002;18:943–4.
15. Wang J, Li W, Li Y. The effect of lower thoracic epidural block on intrapulmonary shunt (Qs/Qt) during one-lung ventilation. J Emerg Med. 2004;26(4):277–9.
16. Chen SS, Fang NX, Zhao Q, Zhang J. The effect of thoracic epidural block on atrial oxygenation and intrapulmonary shunt during one-lung ventilation. J Clin Anesthesiol. 2002;14:432–43.
17. Wu LD, Zhu YM, Zhou Y, Dong LP, Xu GH. Influence of general anesthesia combined with epidural block on the aged during one-lung ventilation in patients undergoing thoracic surgery. Chinese Journal of Clinical Medicine. 2006;16:443–5.
18. Zhang GQ, Wu LD. Clinical observations of influence of general anesthesia combined with epidural block on the aged patients during one-lung ventilation. Acta Academiae Medicinae JiangXi. 2009;49:84–6.
19. Sun Y, Feng Y, Yang BX. Comparison of the effects of isoflurane and propofol in conjunction with thoracic epidural block on oxygenation.
and shunt fraction during one-lung anesthesia. Chin J Anesthesiol. 2002;22:403–5.
20. Pagel PS, John JL, Damask MC, Davis RF, Samuelson PN, Howie MB, et al. Desflurane and isoflurane produce similar alterations in systemic and pulmonary hemodynamics and arterial oxygenation in patients undergoing one-lung ventilation during thoracotomy. Anesth Analg. 1998;87:800–7.
21. Casati A, Mascotto G, Iemi K, Nzepa-Batonga J, de Luca M. Epidural block does not worsen oxygenation during one-lung ventilation for lung resections under isoflurane/nitrous oxide anesthesia. Euro J Anesth. 2005;22:363–8.
22. Freise H, Meissner A, Lauer S, Aellige B, Radke R, Bruewer M, et al. Thoracic epidural analgesia with low concentration of bupivacaine induces thoracic and lumbar sympathetic block. Anesthesiology. 2008;109:107–12.
23. Xu YJ, Tan ZM, Wang S, Shao HJ, Zhu XQ. Effect of thoracic epidural anesthesia with different concentration of Ropivacaine on arterial oxygenation during one-lung ventilation. Anesthesiology. 2010;112:1146–54.
24. Moudgil R, Michelakis D, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol. 2005;98:390.
25. Loepply IA, Scatto P, Reidel CE, Roach RC, Chick TW. Effects of acid/base status on acute pulmonary vasoconstriction and gas exchange. J Appl Physiol. 1993;72:1787–97.
26. Kurilova OA, Vyzhigina MA, Titov VA, Kozlov SP, Zhukova SG, Parshin VD. High level thoracic epidural analgesia as a special component of anesthesia during thoracic surgeries. Anesteziol Reanimatol. 2011;107.
27. Edmark L, Kostova-Aherdan K, Enlund M, Hedenstierna G. Optimal oxygen concentration during induction of general anesthesia. Anesthesiology. 2003;98:28–33.
28. Tumaoğlu S, Tugrul M, Cameli E, Gakar N, Akinci O, Ergin P. Clinical applicability of the substitution of mixed venous oxygen saturation by central venous saturation. J Cardiothorac Vasc Anesth. 2001;15:574–9.
29. Senturk NM, Dilek A, Camci R, Senturk E, Orhan M, Tugrul M, et al. Effects of positive end-expiratory pressure on ventilatory and oxygenation parameters during pressure-controlled one-lung ventilation. J Cardiothorac Vasc Anesth. 2005;19:71–5.